Platform trials arrive on time for glioblastoma

The German National Center for Tumor Diseases (NCT) has developed a noncomparative screening trial called Neuro Master Match (N2M2) for first-line unmethylated glioblastoma (GBM) patients.¹ In the current issue of Neuro-Oncology, the NCT presents pilot data to evaluate feasibility and timeliness of performing complex multilayer molecular diagnostics in a clinical setting to support N2M2. These data are timely in our field, as many platform trials are either ongoing² or planned³ where biomarker data are important for patient allocation. We will first provide a bit more depth on N2M2 and then compare and contrast this trial with 2 other platform trials: the INdividualized Screening trial of Innovative GBM Therapy (INSIGhT)² and the GBM Adaptive Global Innovative Learning Environment (GBM AGILE).³

from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader https://ift.tt/2GuzqZY